Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family

Carole J R Bataille, MB Brennan, S Byrne, SG Davies, M Durbin, O Federov, KVM Huber, Alan Jones, S Knapp, G Liu, A Nadali, CE Quevedo, AJ Russell, RG Walker, R Westwood, GM Wynne

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)
322 Downloads (Pure)


The PIM family of serine/threonine kinases have become an attractive target for anti-cancer drug development, particularly for certain hematological malignancies. Here, we describe the discovery of a series of inhibitors of the PIM kinase family using a high throughput screening strategy. Through a combination of molecular modeling and optimization studies, the intrinsic potencies and molecular properties of this series of compounds was significantly improved. An excellent pan-PIM isoform inhibition profile was observed across the series, while optimized examples show good selectivity over
other kinases. Two PIM-expressing leukemic cancer cell lines, MV4-11 and K562, were employed to evaluate the in vitro anti-proliferative effects of selected inhibitors. Encouraging activities were observed for many examples, with the best example (44) giving an IC50 of 0.75 μM against the K562 cell line. These data provide a promising starting point for further development of this series as a new cancer therapy through PIM kinase inhibition
Original languageEnglish
Pages (from-to)2657-2665
JournalBioorganic & Medicinal Chemistry
Issue number9
Early online date28 Feb 2017
Publication statusPublished - 1 May 2017


Dive into the research topics of 'Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family'. Together they form a unique fingerprint.

Cite this